Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.
02:02am, Tuesday, 10'th Mar 2026
Executives from Crinetics Pharmaceuticals (NASDAQ: CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched
Intech Investment Management LLC Has $926,000 Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX
05:01am, Monday, 09'th Mar 2026
Intech Investment Management LLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
10:37pm, Thursday, 26'th Feb 2026
Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates
07:01pm, Thursday, 26'th Feb 2026
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to a loss of $0.88 per share a year ago.
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 26'th Feb 2026
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of “Moderate Buy” by Analysts
04:46am, Saturday, 07'th Feb 2026
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, Marketbeat repor
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
04:05pm, Thursday, 05'th Feb 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences
Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)
01:25am, Friday, 30'th Jan 2026
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two c
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
05:00pm, Monday, 26'th Jan 2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, Februar
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
04:05pm, Thursday, 22'nd Jan 2026
SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investig
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:56pm, Tuesday, 13'th Jan 2026
Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 12'th Jan 2026
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2026, the Compensation Committee of the Board of Directors granted non-q
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09:22pm, Tuesday, 06'th Jan 2026
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of n
Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data
04:32am, Tuesday, 06'th Jan 2026
Crinetics Pharmaceuticals (NASDAQ: CRNX) provided a corporate update highlighting early commercial progress for Palsonify in acromegaly and new phase 2 data for atumelnant in congenital adrenal hyperp
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:02pm, Monday, 05'th Jan 2026
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of n
